Skip to content
10-Q

Quarterly Report

AVEO Pharmaceuticals, Inc.

0001628280-21-022223

← back to feed
Filed
Nov 8, 2021 12:00 AM ET
Period of report
Restated figures. One or more values in this filing restate previously reported amounts.

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q3 2021 · Nov 1, 2021 34.37M sh
Capex Q3 2021 · Sep 30, 2021 $0
Capex Q3 2021 · Sep 30, 2020 $219K
Cash And Equivalents Q3 2021 · Sep 30, 2021 $68.84M
Cash And Equivalents Q3 2021 · Dec 31, 2020 $61.76M
Current Liabilities Q3 2021 · Sep 30, 2021 $22.38M
Current Liabilities Q3 2021 · Dec 31, 2020 $16.95M
Total Liabilities Q3 2021 · Sep 30, 2021 $57.85M
Total Liabilities Q3 2021 · Dec 31, 2020 $31.62M
Current Assets Q3 2021 · Sep 30, 2021 $107.98M
Current Assets Q3 2021 · Dec 31, 2020 $65.51M
Total Assets Q3 2021 · Sep 30, 2021 $109.09M
Total Assets Q3 2021 · Dec 31, 2020 $66.91M
Shares Diluted restated Q3 2021 · Sep 30, 2020 25.81M sh
Shares Diluted restated Q3 2021 · Sep 30, 2020 19.77M sh
Operating Cash Flow Q3 2021 · Sep 30, 2020 −$25.1M
Stockholders Equity Q3 2021 · Sep 30, 2020 $40.22M
Stockholders Equity Q3 2021 · Jun 30, 2020 $48.02M
Stockholders Equity Q3 2021 · Mar 31, 2020 $7.01M
Stockholders Equity Q3 2021 · Dec 31, 2019 $14.85M
Eps Diluted Q3 2021 · Sep 30, 2020 −$0.33
Eps Diluted Q3 2021 · Sep 30, 2020 −$1.22
Eps Basic Q3 2021 · Sep 30, 2020 −$0.33
Eps Basic Q3 2021 · Sep 30, 2020 −$1.22
Sga Expense Q3 2021 · Sep 30, 2020 $5.8M
Sga Expense Q3 2021 · Sep 30, 2020 $13.21M
Rd Expense Q3 2021 · Sep 30, 2020 $5.86M
Rd Expense Q3 2021 · Sep 30, 2020 $18.11M
Net Income Q3 2021 · Sep 30, 2020 −$8.39M
Net Income Q3 2021 · Sep 30, 2020 −$24.08M
Net Income Q3 2021 · Jun 30, 2020 −$7.31M
Net Income Q3 2021 · Mar 31, 2020 −$8.38M
Operating Income Q3 2021 · Sep 30, 2020 −$8.06M
Operating Income Q3 2021 · Sep 30, 2020 −$26.18M
Revenue Q3 2021 · Sep 30, 2020 $3.6M
Revenue Q3 2021 · Sep 30, 2020 $5.13M